| Literature DB >> 33749980 |
Indira Chandrasekar1, Anne Tourney1, Kamela Loo1, Jason Carmichael1, Kiely James1, Katarzyna A Ellsworth1, David Dimmock1, Maries Joseph1.
Abstract
Hemimegalencephaly (HME) is a rare hamartomatous congenital malformation of the brain characterized by dysplastic overgrowth of either one of the cerebral hemispheres. HME is associated with early onset seizures, abnormal neurological findings, and with subsequent cognitive and behavioral disabilities. Seizures associated with HME are often refractory to antiepileptic medications. Hemispherectomy is usually necessary to provide effective seizure control. The exact etiology of HME is not fully understood, but involves a disturbance in early brain development and likely involves genes responsible for patterning and symmetry of the brain. We present a female newborn who had refractory seizures due to HME. Whole genome sequencing revealed a novel, likely pathogenic, maternally inherited, 3Kb deletion encompassing exon 5 of the NPRL3 gene (chr16:161898-164745x1). The NPRL3 gene encodes for a nitrogen permease regulator 3-like protein, a subunit of the GATOR complex, which regulates the mTOR signaling pathway. A trial of mTOR inhibitor drug, Sirolimus, did not improve her seizure control. Functional hemispherectomy at 3 months of age resulted in total abatement of clinical seizures.Entities:
Keywords: NPRL3 gene; NPRL3 gene variant; hemimegalencephaly; infantile epilepsy; infantile epileptic encepahlopathy; intractable neonatal seizures
Mesh:
Substances:
Year: 2021 PMID: 33749980 DOI: 10.1002/ajmg.a.62185
Source DB: PubMed Journal: Am J Med Genet A ISSN: 1552-4825 Impact factor: 2.802